ライフサイエンスコーパス: antiretroviral agent

1 types associated with drug resistance to any antiretroviral agent.

2 t immunosuppressive agent, or PMPA, a potent antiretroviral agent.

3 metabolism between statins and commonly used antiretroviral agents.

4 new class of immune-stimulating long-acting antiretroviral agents.

5 (HIV-1) infection in combination with other antiretroviral agents.

6 ne receptor 5 antagonists are a new class of antiretroviral agents.

7 gn of new DIS selective ligands as potential antiretroviral agents.

8 to the drug regimen or suboptimal levels of antiretroviral agents.

9 erfamily, confers resistance to purine-based antiretroviral agents.

10 ssed to AIDS and has never been treated with antiretroviral agents.

11 health services and limited or no access to antiretroviral agents.

12 were treated with multidrug combinations of antiretroviral agents.

13 proach to the design of anti-inflamatory and antiretroviral agents.

14 presents an attractive target for developing antiretroviral agents.

15 nate analog, is one of a new class of potent antiretroviral agents.

16 exists, there will be a need for more potent antiretroviral agents.

17 HIV-1 viral load declined in the absence of antiretroviral agents.

18 uld make the zinc finger an ideal target for antiretroviral agents.

19 should be studied in combination with other antiretroviral agents and in persons with more advanced

20 timated by inhibiting virion production with antiretroviral agents and modelling the resulting declin

21 The availability of an increasing number of antiretroviral agents and the rapid evolution of new inf

22 ce is critical for developing more effective antiretroviral agents and therapies.

23 serves as a prototype for this new class of antiretroviral agents and validates gp120 as a viable ta

24 s, review the interaction data with DAAs and antiretroviral agents, and identify the knowledge gaps i

25 The efficacy of antiretroviral agents approved for the treatment of HIV-

26 Furthermore, several antiretroviral agents are active against HBV infection,

27 A wide variety of antiretroviral agents are available through private phar

28 Long-acting injectable antiretroviral agents are being developed for HIV-1 prev

29 Long-term safety data for antiretroviral agents are not yet available.

30 he most recent preclinical advances in novel antiretroviral agents are reviewed and promising new app

31 ic inflammation, immune activation, and some antiretroviral agents, are not taken into account in the

32 Several antiretroviral agents (ARVs) are associated with chronic

33 inhibitor, given with one or two nucleoside antiretroviral agents, as compared with the safety and e

34 re realistic with the development and use of antiretroviral agents, as well as studies on the role of

35 Antiretroviral agents associated with fewer metabolic ef

36 Stavudine is a promising antiretroviral agent, but its clinical efficacy has not

37 integration system is a promising target for antiretroviral agents, but to date no clinically useful

38 Since the efficacy of antiretroviral agents can be impacted by interactions be

39 estoration of anti-mycobacterial immunity by antiretroviral agents can improve the clinical outcome o

40 Currently available antiretroviral agents can suppress viral replication and

41 HIV RNA load is warranted or when preferred antiretroviral agents cannot be used.

42 to 700 cells/mm(3); 48% receiving prescribed antiretroviral agents), comprising 43 asymptomatic indiv

43 ment regimens in the United States contain 3 antiretroviral agents, costing >$30 000/person/year.

44 rase (IN) inhibitors are the newest class of antiretroviral agents developed for the treatment of HIV

45 aternal transmission and may be an effective antiretroviral agent for treatment.

46 nhibitors (ALLINIs) are a promising class of antiretroviral agents for clinical development.

47 ses, including HIV-1, and the application of antiretroviral agents for prevention holds great promise

48 Maturation inhibitors are a new class of antiretroviral agents for treatment of HIV-1.

49 irst-line therapy could be reconsidered when antiretroviral agents from other classes become availabl

50 1 (HIV-1) infection, treatment with a single antiretroviral agent has limited efficacy.

51 Preexposure prophylaxis with antiretroviral agents has been shown to reduce the trans

52 Treatment of HIV disease with antiretroviral agents has changed considerably.

53 ad after initiation of treatment with potent antiretroviral agents has provided substantial insight i

54 IV-1) and the infected host by administering antiretroviral agents has revealed the rapid turnover of

55 Several new antiretroviral agents have been introduced into pediatri

56 known resistance-conferring genotypes to any antiretroviral agent in this cohort of 80 newly infected

57 rformed (Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women Net

58 Therapeutic concentrations of antiretroviral agents in seminal plasma (SP) may reduce

59 r problem affecting the clinical efficacy of antiretroviral agents, including protease inhibitors, in

60 Antiretroviral agents, including those used in recent ye

61 The optimal penetration of antiretroviral agents into the central nervous system ma

62 Although the use of more than one antiretroviral agent is essential for effective HIV-1 tr

63 patients who have been treated with numerous antiretroviral agents, it may be impossible to achieve s

64 Potent antiretroviral agents markedly suppress HIV and have dra

65 stances, the enhanced viral suppression from antiretroviral agents may actually improve or decrease t

66 se, which suggests that early treatment with antiretroviral agents may be indicated for these infants

67 ntial interaction between anti-KS agents and antiretroviral agents needs to be kept in mind.

68 ents with HIV infection who are treated with antiretroviral agents often lose subcutaneous fat and ha

69 go reverse transcription, a step impaired by antiretroviral agents or by introduction of mutations in

70 Thus, following screening of many antiretroviral agents, our findings support only the pot

71 Antiretroviral agents, particularly protease inhibitors

72 Treatment with antiretroviral agents, particularly protease inhibitors,

73 The use of combination antiretroviral agents, particularly the protease inhibit

74 ith HIV/AIDS when treated with highly active antiretroviral agents, persons with HIV infection are th

75 Nelfinavir (NLF), an antiretroviral agent, preserves mitochondrial membranes

76 Antiretroviral agents remain the cornerstone of HIV trea

77 Resistance to antiretroviral agents remains a leading cause of treatme

78 and drug-resistant mutant) and two types of antiretroviral agents (reverse transcriptase and proteas

79 Treatment of HIV-infected individuals with antiretroviral agents selects for drug-resistant mutants

80 aquinavir alone or in combination with other antiretroviral agents should be investigated further.

81 The antiretroviral agent, tenofovir, formulated as a vaginal

82 ent resistance has been demonstrated for all antiretroviral agents tested; therefore, we tested for v

83 Treatment for HIV has relied on the use of antiretroviral agents that can be subject to the develop

84 protease inhibitors are a promising class of antiretroviral agents that compromise enzymatic function

85 ernative to the daily administration of oral antiretroviral agents that has recently shown promise as

86 oviral exposure, the toxicity profile of the antiretroviral agent, the toxicity of the chemotherapy,

87 Despite the large number of approved antiretroviral agents, the number of sequential treatmen

88 rocess of discovering the next generation of antiretroviral agents, this study presents a highly sens

89 Motivated by the ability of combinations of antiretroviral agents to sustain viral suppression in HI

90 ate potency of drugs or suboptimal levels of antiretroviral agents, viral resistance, and other facto

91 leukoencephalopathy who are treated with the antiretroviral agents we used, nor does high-dose antire

92 When antiretroviral agents were coadministered, the 10 U dose

93 ear proof of concept for PRO 140 as a potent antiretroviral agent with extended activity after a sing

94 hough information regarding the use of newer antiretroviral agents with chemotherapy is limited, the

95 IV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action.

96 IDS (RH = 0.83, 95% CI: 0.7, 0.9) and use of antiretroviral agents with protease inhibitors before AI

97 le approaches involve topical application of antiretroviral agents with specific activity against HIV

98 te that FIs constitute an expanding class of antiretroviral agents with the potential to be sequenced

99 Further, treatment with the antiretroviral agent zidovudine either significantly red